Shares of ProNAi Therapeutics, Inc. (NASDAQ:SRRA) traded down 5.4% during trading on Tuesday . The stock traded as low as $2.81 and last traded at $3.00. 1,427,200 shares changed hands during trading, an increase of 295% from the average session volume of 361,577 shares. The stock had previously closed at $3.17.
Several analysts have commented on the stock. ValuEngine upgraded shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Finally, Jefferies Group upgraded shares of ProNAi Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.00.
ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. research analysts expect that ProNAi Therapeutics, Inc. will post -0.85 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/12/07/pronai-therapeutics-srra-stock-price-down-5-4.html.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.